# CTCELLS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ctcells

- Industry: Biotechnology
- Headquarters: Daegu, South Korea
- Website: www.ctcells.com
- Total disclosed funding: $4.5M
- Latest round: Series A (Apr 21, 2021)
- Investors on record: 7

## About

Founded in 2018 and based in Daegu, South Korea, CTCELLS, Inc. operates as a cancer diagnosis and drug development company. The CEO of the company is Kim Min-Seok. In March 2022, CTCELLS, Inc. raised KRW 13 billion in venture funding from returning investors Enlight Ventures, LSK Investment, SK bioscience, and UTC Investment, and new investors InterVest and MiraeAsset Capital.

CTCELLS, Inc. researches circulating tumor cell or CTC-based cancer diagnosis in the blood which is essential to the development of cell therapy based on MBP technology that attaches protein to the NK cell membrane to increase efficacy, and RACE, a dual antibody technology that activates immune cells (Receptor antibody conjugated engager).

The company plans to use the funds for facility investment and recruitment of new personnel. The company also plans to obtain preclinical results for cell therapy and protein therapy programs by the first half of 2023.

## Funding rounds

- Series A, Apr 21, 2021, $4.5M — UTC Investment, KB Securities, LSK Investment, Enlight Ventures, SK bioscience, Chungnam National University Technology Holdings
- Seed, Sep 1, 2020 — Korea Tech Incubator for Startup, Enlight Ventures

## Investors

- Korea Tech Incubator for Startup — Seed
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Seed, Series A
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A
- SK bioscience — Series A
- Chungnam National University Technology Holdings — Series A